Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10099596 | 0.85 | L3MBTL1 (0.61) | KDM4ENPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL13286818 | 0.81 | KDM4E (0.53) | KDM4ENPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL9829017 | 0.81 | MAPK1 (0.69) | KDM4EFOLH1SMN1; SMN2MAPK1 | |
| SCHEMBL10099585 | 0.81 | MAPK1 (0.69) | KDM4EFOLH1SMN1; SMN2MAPK1 | |
| SCHEMBL10099539 | 0.79 | L3MBTL1 (0.69) | NPC1RAB9ASMN1; SMN2L3MBTL1MAPK1 | |
| SCHEMBL29038558 | 0.78 | EPHX2 (0.64) | NAMPTNPC1RAB9ASMN1; SMN2EPHX2 | |
| SCHEMBL27117782 | 0.78 | KDM4E (0.51) | KDM4ENAMPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29038551 | 0.77 | NAAA (0.70) | KDM4ENPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL18534318 | 0.77 | NPC1 (0.56) | FOLH1NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL11282161 | 0.77 | NPC1 (0.53) | KDM4ENPC1RAB9ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093227-B2 | Monosaccharide compounds and methods therefor | ALCHEMIA PTY LTD (AU) | 2012-01-10 | — | — | US | disclosed |
| US-20100184607-A1 | MONOSACCHARIDE COMPOUNDS AND METHODS THEREFOR | ALCHEMIA PTY LTD. (AU) | 2010-07-22 | — | — | US | disclosed |
| US-7417129-B2 | Combinatorial libraries of monosaccharides | ALCHEMIA PTY LTD (AU) | 2008-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184607-A1 | MONOSACCHARIDE COMPOUNDS AND METHODS THEREFOR | SLC5A1, UGGT1, MRPL21 | KDM4E 3609/4885GRM5 2857/4885FOLH1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.